Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

817 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data.
Padwal R, McAlister FA, McMurray JJ, Cowie MR, Rich M, Pocock S, Swedberg K, Maggioni A, Gamble G, Ariti C, Earle N, Whalley G, Poppe KK, Doughty RN, Bayes-Genis A; Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). Padwal R, et al. Among authors: pocock s. Int J Obes (Lond). 2014 Aug;38(8):1110-4. doi: 10.1038/ijo.2013.203. Epub 2013 Oct 31. Int J Obes (Lond). 2014. PMID: 24173404
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced.
Anker SD, Khan MS, Butler J, Ofstad AP, Peil B, Pfarr E, Doehner W, Sattar N, Coats AJS, Filippatos G, Ferreira JP, Zannad F, Pocock S, Packer M. Anker SD, et al. Among authors: pocock s. Eur J Heart Fail. 2023 Jan;25(1):117-127. doi: 10.1002/ejhf.2728. Epub 2022 Nov 24. Eur J Heart Fail. 2023. PMID: 36325584 Free PMC article. Clinical Trial.
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved.
Anker SD, Butler J, Usman MS, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Rocca HPB, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, González-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Iwata T, Schnee JM, Brueckmann M, Pocock SJ, Zannad F. Anker SD, et al. Among authors: pocock sj. Nat Med. 2022 Dec;28(12):2512-2520. doi: 10.1038/s41591-022-02041-5. Epub 2022 Dec 5. Nat Med. 2022. PMID: 36471037 Free PMC article. Clinical Trial.
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause.
Khan MS, Butler J, Anker SD, Filippatos G, Ferreira JP, Pocock SJ, Januzzi JL, Piña IL, Böhm M, Ponikowski P, Verma S, Brueckmann M, Vedin O, Zeller C, Zannad F, Packer M. Khan MS, et al. Among authors: pocock sj. J Am Heart Assoc. 2023 Jan 3;12(1):e027652. doi: 10.1161/JAHA.122.027652. Epub 2022 Dec 24. J Am Heart Assoc. 2023. PMID: 36565199 Free PMC article. Clinical Trial.
Health status across major subgroups of patients with heart failure and preserved ejection fraction.
Siddiqi TJ, Anker SD, Filippatos G, Ferreira JP, Pocock SJ, Böhm M, Brueckmann M, Chopra VK, Iwata T, Januzzi J, Piña IL, Ponikowski P, Senni M, Vedin O, Verma S, Zhang Y, Zannad F, Packer M, Butler J. Siddiqi TJ, et al. Among authors: pocock sj. Eur J Heart Fail. 2023 Sep;25(9):1623-1631. doi: 10.1002/ejhf.2831. Epub 2023 Apr 4. Eur J Heart Fail. 2023. PMID: 36974746
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial.
Butler J, Usman MS, Filippatos G, Ferreira JP, Böhm M, Brueckmann M, Januzzi JL, Kaul S, Piña IL, Ponikowski P, Senni M, Sumin M, Verma S, Zaremba-Pechmann L, Pocock SJ, Packer M, Anker S. Butler J, et al. Among authors: pocock sj. JAMA Cardiol. 2023 Jul 1;8(7):640-649. doi: 10.1001/jamacardio.2023.1090. JAMA Cardiol. 2023. PMID: 37223933 Free PMC article.
817 results